Company news

ALX Oncology Holdings Inc. news in 2023

ALX Oncology Holdings Inc.'s news releases, calls and decks from 2023, newest first.

View company

ALX Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update

November 12, 2023

ALX Oncology Announces November Investor Conference Participation

October 31, 2023

ALX Oncology Announces Closing of Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

October 9, 2023

ALX Oncology Announces Pricing of Public Offering

October 4, 2023

ALX Oncology Announces Proposed Public Offering

October 3, 2023

ALX Oncology Reports Positive Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer

October 2, 2023

ALX Oncology to Host Investor Call and Webcast on October 3, 2023 to Share Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer

October 1, 2023

ALX Oncology Realigns Executive Leadership Team

September 5, 2023

ALX Oncology Announces September Investor Conference Participation

August 30, 2023

ALX Oncology Reports Second Quarter 2023 Financial Results and Provides Clinical Program Update

August 9, 2023

ALX Oncology Receives Orphan Drug Designation from the European Commission for Evorpacept for the Treatment of Patients with Gastric Cancer

June 25, 2023

ALX Oncology Reports First Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights

May 10, 2023

ALX Oncology Announces First Patient Dosed in Phase 2 Investigator-Sponsored Trial of Evorpacept in Patients with Ovarian Cancer

May 8, 2023

ALX Oncology Announces Clinical Trial Collaboration with Sanofi to Evaluate Evorpacept in Combination with SARCLISA (isatuximab-irfc) in Patients with Multiple Myeloma

April 24, 2023

ALX Oncology and Quantum Leap Healthcare Collaborative™ Announce First Patient Dosed in the I-SPY-P1 TRIAL in Breast Cancer

March 12, 2023

ALX Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational Highlights and Upcoming Milestones

March 8, 2023

ALX Oncology Announces First Patient Dosed in ASPEN-07, a Phase 1 Study of Evorpacept for the Treatment of Patients with Urothelial Cancer

February 15, 2023

ALX Oncology Provides Corporate Update and Highlights Key Milestones in 2023

January 4, 2023

ALX Oncology to Present at the 41st Annual J.P. Morgan Healthcare Conference

January 2, 2023